YUHSpace

BROWSE

Export
6 22

Cited 0 times in

Cited 0 times in

Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto

DC Field Value Language
dc.contributor.authorFelip, E.-
dc.contributor.authorCho, B. C.-
dc.contributor.authorNguyen, D.-
dc.contributor.authorCurtin, J. C.-
dc.contributor.authorSethi, S.-
dc.contributor.authorBauml, J. M.-
dc.contributor.authorLee, S. H.-
dc.date.accessioned2025-11-13T00:49:23Z-
dc.date.available2025-11-13T00:49:23Z-
dc.date.created2025-07-16-
dc.date.issued2025-02-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/208726-
dc.description.abstract[No abstract available]-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.titleReply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto-
dc.typeArticle-
dc.contributor.googleauthorFelip, E.-
dc.contributor.googleauthorCho, B. C.-
dc.contributor.googleauthorNguyen, D.-
dc.contributor.googleauthorCurtin, J. C.-
dc.contributor.googleauthorSethi, S.-
dc.contributor.googleauthorBauml, J. M.-
dc.contributor.googleauthorLee, S. H.-
dc.identifier.doi10.1016/j.annonc.2024.10.011-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.pmid39521680-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753424040602-
dc.subject.keywordAmivantamab-
dc.subject.keywordDexamethasone-
dc.subject.keywordLazertinib-
dc.subject.keywordOsimertinib-
dc.subject.keywordEpidermal Growth Factor Receptor-
dc.subject.keywordAmivantamab-
dc.subject.keywordDexamethasone-
dc.subject.keywordLazertinib-
dc.subject.keywordOsimertinib-
dc.subject.keywordTetracycline Derivative-
dc.subject.keywordEpidermal Growth Factor Receptor-
dc.subject.keywordCancer Chemotherapy-
dc.subject.keywordConfidence Interval-
dc.subject.keywordDrug Safety-
dc.subject.keywordFollow Up-
dc.subject.keywordFood And Drug Administration-
dc.subject.keywordHazard Ratio-
dc.subject.keywordHigh Risk Population-
dc.subject.keywordHuman-
dc.subject.keywordInfusion Related Reaction-
dc.subject.keywordLetter-
dc.subject.keywordNon Small Cell Lung Cancer-
dc.subject.keywordOverall Survival-
dc.subject.keywordPatient-reported Outcome-
dc.subject.keywordProgression Free Survival-
dc.subject.keywordQuality Of Life-
dc.subject.keywordRash-
dc.subject.keywordRisk Benefit Analysis-
dc.subject.keywordToxicity-
dc.subject.keywordVenous Thromboembolism-
dc.subject.keywordAdult-
dc.subject.keywordDrug Comparison-
dc.subject.keywordDrug Therapy-
dc.subject.keywordFemale-
dc.subject.keywordLetter-
dc.subject.keywordLung Cancer-
dc.subject.keywordMajor Clinical Study-
dc.subject.keywordMale-
dc.contributor.affiliatedAuthorCho, B. C.-
dc.identifier.scopusid2-s2.0-85210093312-
dc.identifier.wosid001421952900001-
dc.citation.volume36-
dc.citation.number2-
dc.citation.startPage221-
dc.citation.endPage222-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.36(2) : 221-222, 2025-02-
dc.identifier.rimsid87760-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorAmivantamab-
dc.subject.keywordAuthorDexamethasone-
dc.subject.keywordAuthorLazertinib-
dc.subject.keywordAuthorOsimertinib-
dc.subject.keywordAuthorEpidermal Growth Factor Receptor-
dc.subject.keywordAuthorAmivantamab-
dc.subject.keywordAuthorDexamethasone-
dc.subject.keywordAuthorLazertinib-
dc.subject.keywordAuthorOsimertinib-
dc.subject.keywordAuthorTetracycline Derivative-
dc.subject.keywordAuthorEpidermal Growth Factor Receptor-
dc.subject.keywordAuthorCancer Chemotherapy-
dc.subject.keywordAuthorConfidence Interval-
dc.subject.keywordAuthorDrug Safety-
dc.subject.keywordAuthorFollow Up-
dc.subject.keywordAuthorFood And Drug Administration-
dc.subject.keywordAuthorHazard Ratio-
dc.subject.keywordAuthorHigh Risk Population-
dc.subject.keywordAuthorHuman-
dc.subject.keywordAuthorInfusion Related Reaction-
dc.subject.keywordAuthorLetter-
dc.subject.keywordAuthorNon Small Cell Lung Cancer-
dc.subject.keywordAuthorOverall Survival-
dc.subject.keywordAuthorPatient-reported Outcome-
dc.subject.keywordAuthorProgression Free Survival-
dc.subject.keywordAuthorQuality Of Life-
dc.subject.keywordAuthorRash-
dc.subject.keywordAuthorRisk Benefit Analysis-
dc.subject.keywordAuthorToxicity-
dc.subject.keywordAuthorVenous Thromboembolism-
dc.subject.keywordAuthorAdult-
dc.subject.keywordAuthorDrug Comparison-
dc.subject.keywordAuthorDrug Therapy-
dc.subject.keywordAuthorFemale-
dc.subject.keywordAuthorLetter-
dc.subject.keywordAuthorLung Cancer-
dc.subject.keywordAuthorMajor Clinical Study-
dc.subject.keywordAuthorMale-
dc.type.docTypeLetter-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryOncology-
dc.relation.journalResearchAreaOncology-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Show simple item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links